What Is Darobactin? Definition and What Research Reports

Definition

Darobactin is a naturally occurring heptapeptide — a chain of seven amino acids — that belongs to the class of ribosomally synthesised and post-translationally modified peptides (RiPPs). Unlike many bacterial antibiotics assembled by non-ribosomal peptide synthetases, darobactin starts life as a genetically encoded precursor peptide that is then chemically remodelled by a radical SAM enzyme, producing two macrocyclic crosslinks (one ether linkage and one carbon–carbon bond) that lock the molecule into a rigid, fused bicyclic shape. The original compound, darobactin A, was described from Photorhabdus bacteria, symbionts of nematodes that infect insects. In peptide research the term is used two ways: to name the specific molecule darobactin A, and, more loosely, to name the whole darobactin class — a growing family of natural and engineered congeners reviewed in a 2024 overview covering discovery through recent advances (PMID 39028949).

What class of molecule it is and where it comes from

Chemically, darobactin sits at the intersection of peptide chemistry and natural-product antibiotics. The 2024 class review described darobactins as RiPP-derived antibacterial peptides whose defining feature is the fused macrocyclic core installed post-translationally (PMID 39028949). The enzymology behind that core has itself become a research subject: a 2024 study used substrate engineering combined with computation and reported that radical stability governed whether the enzyme formed an ether or a carbon–carbon bond at a given position (PMID 38728535).

Because the scaffold is strained and stereochemically demanding — including an atropisomeric (rotationally restricted) axis — darobactin A became a benchmark target for synthetic chemists. Two independent total syntheses of darobactin A were published in 2022, one reported in the Journal of the American Chemical Society (PMID 35900216) and a second, described as atroposelective, appearing in the same journal (PMID 35926121). Further synthetic studies toward darobactin A have continued to be reported (PMID 41518270).

Quick reference

How the term is used in peptide research

When researchers write "darobactin," they are almost always discussing one of four things: (1) the natural product itself, (2) its mechanism at BamA, (3) synthetic or biosynthetic routes to the scaffold, or (4) engineered derivatives designed to improve antibacterial potency. The term does not refer to a metabolic, cosmetic or performance peptide; the entire published literature around darobactin is antibacterial and structural-biology focused.

A distinctive feature of the field is mutasynthesis and genetic engineering as the main route to analogues. A 2021 report described mutasynthetic production of darobactin analogs and their antimicrobial characterisation (PMID 34937193), and a 2023 paper in Journal of Medicinal Chemistry reported new genetically engineered derivatives of antibacterial darobactins and argued that they underpinned the class's potential for antibiotic development (PMID 38093695).

What the Published Literature Reports

The foundational mechanistic finding came in 2021, when researchers reported in Nature that darobactin mimics a β-strand in order to inhibit the outer membrane insertase BamA — in effect, the peptide docks at the site where BamA would normally engage a nascent β-barrel substrate (PMID 33854236). A complementary 2022 study in Structure monitored darobactin modulating the β-barrel assembly factor BamA, adding biophysical detail to how the peptide engages its target (PMID 34875215).

Structural insight then fed directly back into molecule design. A 2023 report in Angewandte Chemie described darobactins that exhibited superior antibiotic activity following cryo-EM structure-guided biosynthetic engineering (PMID 36308277). One such engineered congener, darobactin D22, was the subject of a 2024 in vivo activity profiling study in ACS Infectious Diseases against critical Gram-negative pathogens (PMID 39565008). More recently, a 2025 Nature Communications paper reported that darobactin A blocked the dynamic lateral gate of the mitochondrial β-barrel biogenesis machinery, extending mechanistic study of the peptide beyond the bacterial outer membrane (PMID 41266328).

Safety and Tolerability: What Studies Report

The darobactin literature available to date is preclinical — microbiological, structural, synthetic and animal work — and does not include published human clinical trials. The 2024 class review summarised the trajectory of the darobactin class from discovery to recent advancements rather than presenting human safety data (PMID 39028949). In vivo characterisation has been reported at the level of animal activity profiling, as in the 2024 study of darobactin D22 against critical Gram-negative pathogens (PMID 39565008). The 2025 finding that darobactin A engaged the mitochondrial β-barrel biogenesis machinery is mechanistically relevant to host-cell considerations and was reported as a structural and functional observation (PMID 41266328). No human dosing information exists in the verified literature, and none is stated here.

Common Points of Confusion

• Darobactin is not a "research peptide" in the bodybuilding sense. It is an antibacterial natural product studied for infectious-disease applications, not a growth, repair or metabolic peptide.
• "Darobactin" often means the class, not one molecule. Papers describe darobactin A alongside engineered variants; the 2023 medicinal chemistry report covered a set of genetically engineered derivatives (PMID 38093695).
• It is not orally available in the way small-molecule antibiotics often are. Published work on the class has centred on structure, biosynthesis and preclinical activity (PMID 39028949).
• Total synthesis ≠ availability. The 2022 syntheses were academic demonstrations of chemical feasibility (PMID 35900216, PMID 35926121).

Regulatory Status

Darobactin has no marketing authorisation from the U.S. Food and Drug Administration or comparable regulators. Material referenced in published studies is handled as a research chemical within laboratory settings. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or treatment decision.

References

• Exploring the Darobactin Class of Antibiotics: A Comprehensive Review from Discovery to Recent Advancements (ACS Infectious Diseases, 2024)
• The antibiotic darobactin mimics a β-strand to inhibit outer membrane insertase (Nature, 2021)
• Monitoring the antibiotic darobactin modulating the β-barrel assembly factor BamA (Structure, 2022)
• Total Synthesis of Darobactin A (Journal of the American Chemical Society, 2022)
• Atroposelective Total Synthesis of Darobactin A (Journal of the American Chemical Society, 2022)
• Synthetic Studies Towards Darobactin A (Chemistry – A European Journal, 2026)
• Mutasynthetic Production and Antimicrobial Characterization of Darobactin Analogs (Microbiology Spectrum, 2021)
• New Genetically Engineered Derivatives of Antibacterial Darobactins Underpin Their Potential for Antibiotic Development (Journal of Medicinal Chemistry, 2023)
• Darobactins Exhibiting Superior Antibiotic Activity by Cryo-EM Structure Guided Biosynthetic Engineering (Angewandte Chemie, 2023)
• Darobactin Substrate Engineering and Computation Show Radical Stability Governs Ether versus C-C Bond Formation (Journal of the American Chemical Society, 2024)
• In Vivo Activity Profiling of Biosynthetic Darobactin D22 against Critical Gram-Negative Pathogens (ACS Infectious Diseases, 2024)
• The dynamic lateral gate of the mitochondrial β-barrel biogenesis machinery is blocked by darobactin A (Nature Communications, 2025)